Summary We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving moderately emetogenic chemotherapy. The study was primarily aimed at investigating the pharmacokinetics and was part of a large multinational, randomised, double-blind, double-dummy efficacy trial. Pharmacokinetic data were obtained in a total of 20 patients, 11 of whom had received a suppository containing ondansetron, and nine patients had received the oral formulation. The median area under the plasma concentration curve (AUC) obtained with the oral formulation was 226 ng ml-lh-' (range 91-750), and the median maximum plasma level (Cmax) was 50.5 ng ml-' (range 24.7-199.6) after a dose of 8 mg. For the ondansetron suppository the median AUC was 140 ng ml -h -1 range (77-405) and the median Cmax was 17.1 ng ml-l (range 13-48.3) after a dose of 16 mg. The systemic exposure after correction for the dose difference after the suppository was on average 70% lower than after the tablet. The median time to reach the maximum level (Tmax) was 60 min (range 28-120) with the oral formulation and 209 min (range 90 -420) with the suppository. For both the tablet and suppository, there was no apparent relationship between either Cmax or AUC, and efficacy. Although the patient numbers were too small for a formal exposure-response relationship to be derived, the slightly poorer pharmacokinetic performance of the suppository did not appear to be associated with a lessening of control of emesis following chemotherapy. The study demonstrates that the pharmacokinetic analysis of a once-daily 16 mg ondansetron suppository results in appropriate plasma concentrations and AUC, and that this rectal formulation is effective in the protection against nausea and vomiting associated with cyclophosphamide chemotherapy. This formulation will provide a useful alternative to the currently available oral formulation.
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Keywords: 5HT3 receptor antagonist; antiemetic Nausea and vomiting are the most distressing aspects of cancer chemotherapy (Coates et al., 1983) . The prevention and treatment of these symptoms was greatly improved with the development of selective 5HT3 receptor antagonists, which yield control of nausea and vomiting in more than 70% of patients treated with highly emetogenic chemotherapy during the first cycle of chemotherapy (Kaasa et al., 1990; Bonneterre et al., 1990; Marschner et al., 1991) . The 5HT3 receptor antagonist ondansetron is rapidly absorped after oral administration and has an absolute bioavailability of approximately 60%. However, oral administration may not be suitable for all patients, especially those who have difficulty in swallowing, or in the outpatient setting in patients whose emesis is poorly controlled. In such cases, an alternative formulation such as a suppository may be useful. Based on pharmacokinetic data from ondansetron suppositories in healthy volunteers, the pharmacokinetic profile and the efficacy of ondansetron given as a 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, was investigated in patients receiving moderately emetogenic chemotherapy. This study was part of a multicentre, multinational, randomised, double-blind, double-dummy, parallel group study, that was primarily aimed at investigating the efficacy, safety and tolerability of the suppository formulation. Pharmacokinetic parameters and emetic protection For the purpose of plotting median plasma concentrations, the time associated with the blood sample due between 9 and 12 h after the dose was depicted as 12 h. In the estimation of the individual AUC value, the actual time of sample collection was used. Quantification of ondansetron in the samples from two of the patients receiving active oral treatment was not possible due to co-eluting interferences. The predose sample of these two patients was free of interfering peaks. The presence of these co-eluting interferences in the samples was confirmed by the use of the UV photodiode array (UV-PDA) detector. Although the interfering peak had a retention time close to ondansetron, the UV spectrum was distinct from that of ondansetron. In the UV spectra taken at the rising slope of the peak, we demonstrated the presence of ondansetron, whereas at the apex and descending slope the interference was abundantly present. No interferences could be detected in the UV spectra of the other patients. The nature and origin of the interfering compounds could not be determined. No ondansetron was detectable in the samples from one patient scheduled to receive the active suppository. This finding is not consistent with previous findings in healthy volunteers and other patients. The first recorded bowel movement in this patient was approximately 9 l/2 h post dose and it is therefore unlikely that the suppository was voided before any significant ondansetron absorption having occurred. It was Pharmacokineics and efficacy of a once-daily ondanestron suppository R de WR et al W! 325 considered that this patient had not administered the suppository properly and the patient was excluded from the pharmacokinetic assessment.
Patients and methods
The Cmax and AUCs of ondansetron varied widely between patients (Table I) . Relatively high levels (> 100 ng ml-') were reached in three patients who received the oral formulation. In these patients the peak levels were reached early in the course of the concentration-time curves. By examination of the medical files it was verified that these patients had not received additional ondansetron medication in the first 24 h period. Figure 1 shows the median plasma ondansetron concentrations. The median area under the plasma concentration curve (AUC) obtained with the oral formulation was 226 ng ml-'h-' (range 91-750), and the median maximum plasma level (Cm,,) was 50.5 ng ml-' (range 24.7-199.6). For the ondansetron suppository the median AUC was 140 ng ml-'h-' range (77-405) and the median Cma,, was 17.1 ng ml-' (range 13-48.3). The difference between the dose-corrected AUC values after administration of the oral formulation and the suppository revealed statistical significance (P<0.01). The Cma,, value after the tablet was significantly higher than after the suppository (P<0.01). The ratio of the median AUC values after rectal and oral administration after correction for the difference in dose illustrates that the systemic availability after rectal administration in this group of patients is approximately 70% lower than after oral administration. The median time to reach the maximum level (TmaX) was 60 min (range 28-120) with the oral formulation, and 209 min (range 90-420) with the suppository (P<0.01). The plasma ondansetron concentration-time profiles from the ten evaluable patients receiving a 16 mg suppository once daily were generally lower than the median profile (although essentially contained within the range of concentrations) observed in the patients receiving the oral formulation. The systemic exposure after the rectal administration was, corrected for the dose difference, on average 70% lower than after oral administration. The difference was statistically significant. The (Pritchard, 1992) that there is no clear pharmacokinetic -pharmacodynamic relationship within the range of Cmax, 4 h concentration and AUC observed in this study. A similar finding has been reported (Cupissol et al., 1993) for another 5-HT3 antagonist, granisetron, despite greater interpatient variability in AUC than seen here. The lack of any apparent relationship between exposure and efficacy may, however, be due in part to the small patient numbers involved and the relatively heterogenous nature of the patient groups. The lower plasma levels obtained with the suppository in some subjects in this study did not appear to be associated with a lessening of control of emesis following chemotherapy.
This study demonstrates that the pharmacokinetic analysis of a once-daily 16 mg ondansetron suppository results in plasma concentrations and AUC that are adequately effective against nausea and vomiting associated with cyclophosphamide chemotherapy. This formulation will provide a useful alternative to the currently available oral formulation.
